• Most Popular
  • Most Shared

Celgene pulls out of GPC prostate cancer drug deal

Wed Aug 6, 2008 6:19pm EDT

Stocks

   

LOS ANGELES, Aug 6 (Reuters) - GPC Biotech AG GPCG.DE said on Wednesday that Celgene Corp (CELG.O) has terminated its co-development and license agreement for GPC's experimental prostate cancer drug satraplatin.

Stocks  |  Global Markets

Rights to the drug in Europe, Turkey, the Middle East, Australia and New Zealand will be returned to GPC Biotech.

The company said last month it had withdrawn the European marketing application for satraplatin after regulators indicated it was not approvable based on the information provided.

GPC said last October the drug had failed a late-stage clinical trial and it would no longer seek U.S. regulatory approval. (Reporting by Deena Beasley, Editing by Andre Grenon)

Stocks
Global Markets


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
A hiring sign hangs in a window at PETCO in Falls Church, Virginia June 5, 2009.REUTERS/Kevin Lamarque

Dust off your resumes

Employers say they'll be adding headcount in the coming year. Here's where the jobs will be.  Full Article 

ECONOMY
A traveller lifts her arms as she stands in the new security scan at Schiphol airport, Netherlands, May 15, 2007.REUTERS/Jerry Lampen

Are you ok getting "naked"?

Full-body scanners can detect weapons under clothing but also expose passengers to operators. Should security trump privacy?  Full Article | Video 

U.S.